Welcome to our dedicated page for Scisparc news (Ticker: SPRC), a resource for investors and traders seeking the latest updates and insights on Scisparc stock.
SciSparc Ltd. (Nasdaq: SPRC) generates news across clinical-stage pharmaceuticals, intellectual property, medical devices, and advanced computing initiatives. Through its majority-owned subsidiary NeuroThera Labs Inc., the company reports progress on cannabinoid-based drug candidates, patent grants, and collaborations targeting central nervous system and neuropsychiatric disorders.
Investors following SPRC news can expect updates on drug development programs such as SCI-110, for Tourette syndrome and for the treatment of Alzheimer’s disease and agitation, and SCI-210, for autism spectrum disorder (ASD) and status epilepticus. Company announcements also cover patent activity, including NeuroThera’s opioid–N-acylethanolamine platform for pain management and MEAI-based combination therapies for depression and addiction-related indications.
SciSparc’s news flow extends to corporate transactions and strategic repositioning. Recent disclosures include the transfer of its advanced clinical-stage pharmaceutical portfolio and its stake in SciSparc Nutraceuticals Inc. into NeuroThera Labs Inc., the sale of oncology-focused subsidiary MitoCareX Bio Ltd. to N2OFF, Inc., and a binding term sheet followed by a definitive agreement to acquire a treasury of patents and trademarks for innovative endoscopic systems and medical cameras, including the MUSE system for GERD treatment.
Another recurring theme in SPRC news is technology-driven R&D. The company has announced a quantum computing-enabled 3D protein modeling initiative aimed at improving drug discovery, as well as a non-binding term sheet for NeuroThera to acquire a majority stake in a quantum bio data analysis company. Regulatory and capital markets items, such as Nasdaq compliance notifications, warrant inducement agreements, and SEC Form 6-K filings, also appear in its news stream. For a structured view of these developments, the SciSparc news page aggregates press releases and related coverage in one place.
SciSparc Ltd. (Nasdaq: SPRC) has initiated preparations for an Investigational New Drug Application (IND) with the FDA for a Phase IIb clinical trial of its drug, SCI-110, targeting Tourette Syndrome (TS). Following promising Phase IIa trial results showing a 21% reduction in tic symptoms among treatment-resistant patients, the company aims to expand clinical sites to the U.S. Approval has been granted by two medical centers in Germany and Israel to participate in the upcoming trial, which will evaluate treatment efficacy and safety.
SciSparc Ltd. (Nasdaq: SPRC) announced the launch of its new advanced facility in Ness-Ziona Science Park, Israel, through its joint venture MitoCareX Bio, aimed at developing anti-cancer drug candidates. This facility underscores the company’s commitment to addressing the global cancer crisis, which accounted for nearly 10 million deaths in 2020. MitoCareX Bio will focus on mitochondrial carriers critical for cell viability and is enhancing its computational drug discovery capabilities, building upon successful proof-of-concept research conducted in the U.K.
SciSparc Ltd. (Nasdaq: SPRC) has announced a $1 million share buyback program, aimed at enhancing shareholder value. The program will require court approval in Israel and is contingent upon the formal approval of financial statements for the six months ending June 30, 2022. The company is engaged in developing cannabinoid-based therapies targeting conditions such as Tourette syndrome, Alzheimer's disease, and autism spectrum disorder. This move reflects SciSparc's commitment to delivering shareholder returns amidst ongoing clinical trials.
SciSparc Ltd. (Nasdaq: SPRC) has announced the successful development of its drug candidate SCI-110 for an upcoming Phase IIb trial targeting Tourette Syndrome (TS). The company received ethics committee approvals from institutions in Germany and Israel for the study. SCI-110 aims to provide a safe treatment option for patients with limited alternatives. The multinational study will evaluate the drug's efficacy and safety in adults aged 18-65, focusing on tic severity changes. The trial's launch awaits further regulatory approvals.
SciSparc Ltd. (NASDAQ: SPRC) has received approval from the Soroka University Ethics Committee to conduct a clinical trial for its proprietary drug SCI-210, targeting Autism Spectrum Disorder (ASD). This trial aims to evaluate the safety, tolerability, and efficacy of SCI-210, a combination of cannabidiol and CannAmide™, compared to CBD monotherapy in 60 children over 20 weeks. The approval marks a significant milestone for SciSparc in its pursuit of developing effective treatments for pediatric patients with limited options.
SciSparc Ltd. (Nasdaq: SPRC) announced the appointment of Prof. Ciro Leonardo Pierri as a special advisor for MitoCareX Bio Ltd., its new joint venture focused on drug development for cancers and infectious diseases. Prof. Pierri, a biochemist from the University of Bari, Italy, brings expertise in structural biology and molecular modeling. The JV aims to explore mitochondrial carriers' roles in disease treatment, building on successful proof-of-concept experiments in the UK. SciSparc is engaged in cannabinoid-based drug development, targeting conditions like Tourette syndrome and Alzheimer’s disease.
SciSparc Ltd. (Nasdaq: SPRC) announced a review of potential strategic transactions aimed at maximizing shareholder value. The board is considering various options, including investments, acquisitions, partnerships, or licensing its technologies. CEO Oz Adler highlighted the company's strong cash position, allowing for exploration of external alternatives while continuing its existing business strategy. The firm remains focused on developing treatments for central nervous system disorders, including Alzheimer’s and Tourette syndrome, while adhering to FDA guidelines.
SciSparc Ltd. (NASDAQ: SPRC) announced positive initial pre-clinical results for a treatment for cocaine addiction using MEAI, a novel psychedelic molecule from Clearmind Medicine Inc. (CSE: CMND). The collaborative provisional patent application was filed to explore treatment potential based on SciSparc's CannAmide™ compound and Clearmind's MEAI. The trials indicated that MEAI could reduce cocaine's reward effects in rats, presenting a potential breakthrough in cocaine addiction treatment. The study was conducted by Professor Gal Yadid at Bar Ilan University.
SciSparc Ltd. (NASDAQ: SPRC) has completed a $10 million private placement priced at-the-market, facilitated by Aegis Capital Corp. as the exclusive placement agent. The company is focused on developing cannabinoid-based pharmaceuticals, including SCI-110 for Tourette syndrome and SCI-160 for pain management. These projects aim to target various ailments such as Alzheimer's and autism. The private placement reflects investor confidence in SciSparc's innovative drug development pipeline.
SciSparc Ltd. (NASDAQ: SPRC) has announced a collaboration with Clearmind Medicine Inc. to file a provisional patent for a treatment targeting cocaine addiction. This involves a combination of SciSparc's CannAmide™ and Clearmind's MEAI, addressing the significant issue of cocaine addiction affecting over 1.3 million Americans. Current statistics highlight more than 350,000 hospital visits annually linked to cocaine use and around 16,000 overdose deaths. The collaboration aims to explore potential therapeutic solutions for addictions, with ongoing efforts to strengthen their partnership.